Aptose Reports Results for the First Quarter 2023
<!-- Name:DistributionId Value:8834370 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
$apto
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual…
<!-- Name:DistributionId Value:8804897 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday,…
SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company…
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on…
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated…
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company…
CORRECTION — Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June…
Aptose Presents Highlights from Corporate Update and KOL Event
HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results SAN DIEGO and TORONTO, June 02,…
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company…
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd
SAN DIEGO and TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral…
Aptose Reports Results for the First Quarter 2022
Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE…